{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:32:07Z","timestamp":1772119927618,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012295","name":"NIHR Newcastle Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012295","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Skeletal muscle nicotinamide adenine dinucleotide (NAD) concentrations are low in people with sarcopenia. Increasing NAD concentrations may offer a novel therapy. This study tested if acipimox (a NAD precursor) improves skeletal muscle NAD concentration and function in people with probable sarcopenia. Participants aged 65 and over with low walk speed (&lt;\u20090.8\u00a0m\/s) and low muscle strength (by 2019 European Working Group criteria) were recruited to this before and after, proof-of-concept study. Participants received acipimox 250\u00a0mg orally (twice or thrice daily according to creatinine clearance)\u2009+\u2009aspirin 75\u00a0mg daily (to prevent facial flushing) for 4\u00a0weeks. Muscle biopsy of the vastus lateralis,\n                      <jats:sup>31<\/jats:sup>\n                      P magnetic resonance spectroscopy and a 7-digital mobility assessment were performed before starting acipimox and after 3\u00a0weeks of treatment. The primary outcome was change in skeletal muscle NAD concentration. Secondary outcomes included change in phosphocreatine recovery rate and measures of physical performance. Eleven participants (8 women), mean age 78.9\u00a0years (SD 4.3), were recruited. Mean walk speed at baseline was 0.69\u00a0m\/s (SD 0.07). All completed baseline and follow-up visits. Median medication adherence was 95% (range 91\u2013104%). There was no statistically significant difference in the primary outcome of change in NAD concentrations in skeletal muscle between baseline and follow-up [median difference:\u2009\u2212\u20090.003 umol\/g (IQR\u2009\u2212\u20090.058 to 0.210);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.26] or secondary outcomes. Nineteen none-serious adverse events were reported. Although the study protocol was feasible and well tolerated, acipimox did not improve skeletal muscle NAD concentration, biochemical markers or physical function in people with probable sarcopenia. ClinicalTrials.gov Identifier: ISRCTN (ISRCTN87404878).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11357-025-01606-9","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T03:47:53Z","timestamp":1742269673000},"page":"6065-6078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of acipimox on skeletal muscle biochemistry, structure and function in older people with probable sarcopenia: an experimental medicine study"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7592-9952","authenticated-orcid":false,"given":"Claire","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Alderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G.","family":"Birkbeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Del Din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gr\u00e1inne S.","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieren G.","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Massarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Rochester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen A. L.","family":"Tuppen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avan A.","family":"Sayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles D.","family":"Witham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"10191","key":"1606_CR1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Sayer AA. Sarcopenia. The Lancet. 2019;393(10191):2636\u201346.","journal-title":"The Lancet"},{"key":"1606_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.maturitas.2017.04.007","volume":"103","author":"P Liu","year":"2017","unstructured":"Liu P, Hao Q, Hai S, Wang H, Cao L, Dong B. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis. Maturitas. 2017;103:16\u201322.","journal-title":"Maturitas"},{"issue":"3","key":"1606_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/jcsm.12411","volume":"10","author":"SS Yeung","year":"2019","unstructured":"Yeung SS, Reijnierse EM, Pham VK, Trappenburg MC, Lim WK, Meskers CG, Maier AB. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(3):485\u2013500.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"1606_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-024-00550-w","volume":"10","author":"AA Sayer","year":"2024","unstructured":"Sayer AA, Cooper R, Arai H, Cawthon PM, Ntsama Essomba MJ, Fielding RA, et al. Sarcopenia. Nat Rev Dis Primers. 2024;10(1):68.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1606_CR5","doi-asserted-by":"publisher","first-page":"afac003","DOI":"10.1093\/ageing\/afac003","volume":"51","author":"C Hurst","year":"2022","unstructured":"Hurst C, Robinson SM, Witham MD, Dodds RM, Granic A, Buckland C, et al. Resistance exercise as a treatment for sarcopenia: prescription and delivery. Age Ageing. 2022;51(2):afac003.","journal-title":"Age Ageing"},{"issue":"3\u20134","key":"1606_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1515\/teb-2024-0030","volume":"1","author":"CS Deane","year":"2024","unstructured":"Deane CS, Willis CR, Gallagher IJ, Brook MS, Gharahdaghi N, Wylie LJ, et al. Nicotinic acid improves mitochondrial function and associated transcriptional pathways in older inactive males. Transl Exercise Biomed. 2024;1(3\u20134):277\u201394.","journal-title":"Transl Exercise Biomed"},{"issue":"1","key":"1606_CR7","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1038\/s41467-019-13694-1","volume":"10","author":"E Migliavacca","year":"2019","unstructured":"Migliavacca E, Tay SK, Patel HP, Sonntag T, Civiletto G, McFarlane C, et al. Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. Nat Commun. 2019;10(1):5808.","journal-title":"Nat Commun"},{"issue":"3","key":"1606_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s42255-024-00997-x","volume":"6","author":"M Membrez","year":"2024","unstructured":"Membrez M, Migliavacca E, Christen S, Yaku K, Trieu J, Lee AK, et al. Trigonelline is an NAD+ precursor that improves muscle function during ageing and is reduced in human sarcopenia. Nat Metab. 2024;6(3):433\u201347.","journal-title":"Nat Metab"},{"issue":"Suppl 1","key":"1606_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40279-022-01772-2","volume":"52","author":"D Campelj","year":"2022","unstructured":"Campelj D, Philp A. NAD+ Therapeutics and skeletal muscle adaptation to exercise in humans. Sports medicine (Auckland, NZ). 2022;52(Suppl 1):91\u20139.","journal-title":"Sports medicine (Auckland, NZ)"},{"issue":"10","key":"1606_CR10","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1093\/jn\/nxab193","volume":"151","author":"NJ Connell","year":"2021","unstructured":"Connell NJ, Grevendonk L, Fealy CE, Moonen-Kornips E, Bruls YMH, Schrauwen-Hinderling VB, et al. NAD+-precursor supplementation with L-tryptophan, nicotinic acid, and nicotinamide does not affect mitochondrial function or skeletal muscle function in physically compromised older adults. J Nutr. 2021;151(10):2917\u201331.","journal-title":"J Nutr"},{"issue":"4","key":"1606_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/crt2.56","volume":"7","author":"FJ Barker","year":"2022","unstructured":"Barker FJ, Hart A, Sayer AA, Witham MD. Effects of nicotinamide adenine dinucleotide precursors on measures of physical performance and physical frailty: a systematic review. JCSM Clinical Reports. 2022;7(4):93\u2013106.","journal-title":"JCSM Clinical Reports"},{"issue":"1","key":"1606_CR12","first-page":"9","volume":"2","author":"M Igarashi","year":"2023","unstructured":"Igarashi M, Yamauchi T. Insight into the application of nicotinamide mononucleotide (NMN) to age-related disorders. J Cellular Mole. 2023;2(1):9\u201313.","journal-title":"J Cellular Mole"},{"issue":"4","key":"1606_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2337\/db14-0667","volume":"64","author":"T Van De Weijer","year":"2015","unstructured":"Van De Weijer T, Phielix E, Bilet L, Williams EG, Ropelle ER, Bierwagen A, et al. Evidence for a direct effect of the NAD+ precursor acipimox on muscle mitochondrial function in humans. Diabetes. 2015;64(4):1193\u2013201.","journal-title":"Diabetes"},{"issue":"6","key":"1606_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1007\/s00125-019-4831-3","volume":"62","author":"NJ Connell","year":"2019","unstructured":"Connell NJ, Houtkooper RH, Schrauwen P. NAD+ metabolism as a target for metabolic health: have we found the silver bullet? Diabetologia. 2019;62(6):888\u201399.","journal-title":"Diabetologia"},{"key":"1606_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/BF02657054","volume":"39","author":"A Edlund","year":"1990","unstructured":"Edlund A, Musatti L, Wennmalm \u00c5. Acipimox stimulates skin blood flow by a cyclo-dxygenase-dependent mechanism. Eur J Clin Pharmacol. 1990;39:37\u201341.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1606_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076518","volume":"14","author":"C McDonald","year":"2024","unstructured":"McDonald C, Alderson C, Birkbeck MG, Brown L, Del Din S, Gorman GG, et al. A study protocol to investigate if acipimox improves muscle function and sarcopenia: an open-label, uncontrolled, before-and-after experimental medicine feasibility study in community-dwelling older adults. BMJ Open. 2024;14(2): e076518.","journal-title":"BMJ Open"},{"issue":"1","key":"1606_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331.","journal-title":"Age Ageing"},{"issue":"3","key":"1606_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.22540\/JFSF-04-071","volume":"4","author":"NJ Offord","year":"2019","unstructured":"Offord NJ, Clegg A, Turner G, Dodds RM, Sayer AA, Witham MD. Current practice in the diagnosis and management of sarcopenia and frailty\u2013results from a UK-wide survey. J Frailty, Sarcopenia Falls. 2019;4(3):71.","journal-title":"J Frailty, Sarcopenia Falls"},{"issue":"3","key":"1606_CR19","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146\u201357.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"1606_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12877-020-1463-x","volume":"20","author":"MD Witham","year":"2020","unstructured":"Witham MD, Wason J, Dodds R, Sayer AA. Developing a composite outcome measure for frailty prevention trials \u2013 rationale, derivation and sample size comparison with other candidate measures. BMC Geriatrics. 2020;20(1):113.","journal-title":"BMC Geriatrics"},{"issue":"1","key":"1606_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"key":"1606_CR22","unstructured":"Pfizer ltd. Summary of product characteristics olbetam capsules 250. Electronic Medicines compendium. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/1357\/smpc. Accessed 11\/03\/2025."},{"issue":"1","key":"1606_CR23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1046\/j.1432-1327.1998.2570192.x","volume":"257","author":"WK Porteous","year":"1998","unstructured":"Porteous WK, James AM, Sheard PW, Porteous CM, Packer MA, Hyslop SJ, et al. Bioenergetic consequences of accumulating the common 4977-bp mitochondrial DNA deletion. Eur J Biochem. 1998;257(1):192\u2013201.","journal-title":"Eur J Biochem"},{"issue":"910","key":"1606_CR24","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/BF01753355","volume":"21","author":"SL Old","year":"1989","unstructured":"Old SL, Johnson MA. Methods of microphotometric assay of succinate-dehydrogenase and cytochrome-C oxidase activities for use on human skeletal-muscle. Histochem J. 1989;21(910):545\u201355.","journal-title":"Histochem J"},{"issue":"1","key":"1606_CR25","doi-asserted-by":"publisher","first-page":"15037","DOI":"10.1038\/srep15037","volume":"5","author":"MC Rocha","year":"2015","unstructured":"Rocha MC, Grady JP, Gr\u00fcnewald A, Vincent A, Dobson PF, Taylor RW, et al. A novel immunofluorescent assay to investigate oxidative phosphorylation deficiency in mitochondrial myopathy: understanding mechanisms and improving diagnosis. Sci Rep-Uk. 2015;5(1):15037.","journal-title":"Sci Rep-Uk"},{"issue":"12","key":"1606_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114462","volume":"9","author":"JP Grady","year":"2014","unstructured":"Grady JP, Murphy JL, Blakely EL, Haller RG, Taylor RW, Turnbull DM, Tuppen HAL. Accurate measurement of mitochondrial DNA deletion level and copy number differences in human skeletal muscle. PLoS ONE. 2014;9(12): e114462.","journal-title":"PLoS ONE"},{"issue":"2","key":"1606_CR27","doi-asserted-by":"publisher","first-page":"M85","DOI":"10.1093\/geronj\/49.2.M85","volume":"49","author":"JM Guralnik","year":"1994","unstructured":"Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):M85-94.","journal-title":"J Gerontol"},{"issue":"4","key":"1606_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/ageing\/afr051","volume":"40","author":"HC Roberts","year":"2011","unstructured":"Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423\u20139.","journal-title":"Age Ageing"},{"issue":"1","key":"1606_CR29","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1038\/s41598-024-51766-5","volume":"14","author":"C Kirk","year":"2024","unstructured":"Kirk C, K\u00fcderle A, Mic\u00f3-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, et al. Mobilise-D insights to estimate real-world walking speed in multiple conditions with a wearable device. Sci Rep-Uk. 2024;14(1):1754.","journal-title":"Sci Rep-Uk"},{"issue":"1","key":"1606_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12984-023-01198-5","volume":"20","author":"ME Mic\u00f3-Amigo","year":"2023","unstructured":"Mic\u00f3-Amigo ME, Bonci T, Paraschiv-Ionescu A, Ullrich M, Kirk C, Soltani A, et al. Assessing real-world gait with digital technology? Validation, insights and recommendations from the Mobilise-D consortium. J NeuroEng Rehab. 2023;20(1):78.","journal-title":"J NeuroEng Rehab"},{"issue":"9","key":"1606_CR31","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cgh.2008.04.013","volume":"6","author":"KG Hollingsworth","year":"2008","unstructured":"Hollingsworth KG, Newton JL, Taylor R, McDonald C, Palmer JM, Blamire AM, Jones DEJ. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol H. 2008;6(9):1041\u20138.","journal-title":"Clin Gastroenterol H"},{"issue":"2","key":"1606_CR32","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1148\/radiol.14141191","volume":"275","author":"T Loughran","year":"2015","unstructured":"Loughran T, Higgins DM, McCallum M, Coombs A, Straub V, Hollingsworth KG. Improving highly accelerated fat fraction measurements for clinical trials in muscular dystrophy: origin and quantitative effect of R2* changes. Radiology. 2015;275(2):570\u20138.","journal-title":"Radiology"},{"issue":"2","key":"1606_CR33","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/jcsm.12934","volume":"13","author":"M Achison","year":"2022","unstructured":"LACE Study Group, Achison M, Adamson S, Akpan A, Aspray T, Avenell A, et al. Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial. J Cachexia, Sarcopenia Muscle. 2022;13(2):858\u201371.","journal-title":"J Cachexia, Sarcopenia Muscle"},{"issue":"2","key":"1606_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/rco2.38","volume":"4","author":"MD Witham","year":"2021","unstructured":"Witham MD, Achison M, Aspray TJ, Avenell A, Band MM, Donnan PT, et al. Recruitment strategies for sarcopenia trials: lessons from the LACE randomized controlled trial. JCSM rapid communications. 2021;4(2):93\u2013102.","journal-title":"JCSM rapid communications"},{"issue":"3","key":"1606_CR35","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/jcsm.13004","volume":"13","author":"AL Clark","year":"2022","unstructured":"Clark AL, Abel AAI. Treating sarcopenia: the LACE trial. J Cachexia, Sarcopenia Muscle. 2022;13(3):1437\u20139.","journal-title":"J Cachexia, Sarcopenia Muscle"},{"key":"1606_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13104-018-3947-8","volume":"11","author":"D Wilson","year":"2018","unstructured":"Wilson D, Breen L, Lord JM, Sapey E. The challenges of muscle biopsy in a community based geriatric population. BMC Res Notes. 2018;11:1\u20136.","journal-title":"BMC Res Notes"},{"issue":"7","key":"1606_CR37","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1210\/js.2017-00092","volume":"1","author":"YS Elhassan","year":"2017","unstructured":"Elhassan YS, Philp AA, Lavery GG. Targeting NAD+ in metabolic disease: new insights into an old molecule. J Endocrine Soc. 2017;1(7):816\u201335.","journal-title":"J Endocrine Soc"},{"issue":"6","key":"1606_CR38","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s11010-022-04408-1","volume":"477","author":"S Wagner","year":"2022","unstructured":"Wagner S, Manickam R, Brotto M, Tipparaju SM. NAD+ centric mechanisms and molecular determinants of skeletal muscle disease and aging. Mol Cell Biochem. 2022;477(6):1829\u201348.","journal-title":"Mol Cell Biochem"},{"issue":"7","key":"1606_CR39","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.celrep.2019.07.043","volume":"28","author":"YS Elhassan","year":"2019","unstructured":"Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717-28.e6.","journal-title":"Cell Rep"},{"issue":"8","key":"1606_CR40","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.2337\/db13-1130","volume":"63","author":"G Daniele","year":"2014","unstructured":"Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D, et al. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals. Diabetes. 2014;63(8):2812\u201320.","journal-title":"Diabetes"},{"key":"1606_CR41","first-page":"2015","volume":"101","author":"H Makimura","year":"2015","unstructured":"Makimura H, Stanley T, Suresh C, De Sousa-Coelho AL, Frontera W, Syu S, et al. Metabolic effects of long-term reduction in free fatty acids with acipimox in obesity: a randomized trial. J Clin Endocrinol Metab. 2015;101:2015\u20133696.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1606_CR42","first-page":"143","volume":"16","author":"S Cameron","year":"2012","unstructured":"Cameron S, Goulopoulou S, Weil B, Kanaley J. Regulation of blood flow by aspirin following muscle ischemia. Eur Rev Med Pharmacol Sci. 2012;16(2):143\u201350.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"12","key":"1606_CR43","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14471","volume":"8","author":"RT Junejo","year":"2020","unstructured":"Junejo RT, Ray CJ, Marshall JM. Prostaglandin contribution to postexercise hyperemia is dependent on tissue oxygenation during rhythmic and isometric contractions. Physiol Rep. 2020;8(12): e14471.","journal-title":"Physiol Rep"},{"issue":"4","key":"1606_CR44","doi-asserted-by":"publisher","first-page":"H1220","DOI":"10.1152\/ajpheart.00475.2010","volume":"299","author":"M Halbirk","year":"2010","unstructured":"Halbirk M, N\u00f8rrelund H, M\u00f8ller N, Schmitz O, G\u00f8tzsche L, Nielsen R, et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol-Heart Circ Physiol. 2010;299(4):H1220\u20135.","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"3","key":"1606_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00228-021-03250-6","volume":"78","author":"LA Garc\u00eda Rodr\u00edguez","year":"2022","unstructured":"Garc\u00eda Rodr\u00edguez LA, Cea Soriano L, de Abajo FJ, Valent F, Hallas J, Gil M, et al. Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study. Eur J Clin Pharmacol. 2022;78(3):497\u2013505. https:\/\/doi.org\/10.1007\/s00228-021-03250-6.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1606_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101329","volume":"47","author":"P Raeisi-Giglou","year":"2022","unstructured":"Raeisi-Giglou P, Jabri A, Shahrori Z, Sallam S, Alhuneafat L, Al-Abdouh A, et al. Disparities in the prescription of statins in the primary care setting: a retrospective observational study. Curr Probl Cardiol. 2022;47(11): 101329.","journal-title":"Curr Probl Cardiol"},{"issue":"9","key":"1606_CR47","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/bcp.13299","volume":"83","author":"SY Loo","year":"2017","unstructured":"Loo SY, Dell\u2019Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096\u2013106.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1606_CR48","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s43587-022-00174-3","volume":"2","author":"GE Janssens","year":"2022","unstructured":"Janssens GE, Grevendonk L, Perez RZ, Schomakers BV, de Vogel-van-den bosch J, Geurts JM, et al. Healthy aging and muscle function are positively associated with NAD+ abundance in humans. Nature Aging. 2022;2(3):254\u201363.","journal-title":"Nature Aging"},{"issue":"5","key":"1606_CR49","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cmet.2018.03.016","volume":"27","author":"MG Tarrag\u00f3","year":"2018","unstructured":"Tarrag\u00f3 MG, Chini CCS, Kanamori KS, Warner GM, Caride A, de Oliveira GC, et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD(+) decline. Cell Metab. 2018;27(5):1081-95.e10.","journal-title":"Cell Metab"},{"issue":"4","key":"1606_CR50","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","volume":"39","author":"EN Chini","year":"2018","unstructured":"Chini EN, Chini CCS, Espindola Netto JM, de Oliveira GC, van Schooten W. The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging. Trends Pharmacol Sci. 2018;39(4):424\u201336.","journal-title":"Trends Pharmacol Sci"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01606-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01606-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01606-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T09:55:00Z","timestamp":1757152500000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01606-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":50,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01606-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.28.24318143","asserted-by":"object"}]},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by North East\u2014Tyne & Wear South Research Ethics Committee REC reference: 21\/NE\/0100. All participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"The authors consent for publication in Geroscience.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MDW: Rejuvenate BioMed consultancy.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}